Karyopharm Therapeutics Inc. cotiza a 0.43 USD y tiene una capitalización bursátil de $10M. En los últimos 12 meses ha facturado $147M con un margen de flujo de caja libre del -51.6%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of …
| Periodo | 2026-08 | 2026-05 | 2026-02 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-1.24 | $-2.23 | $-3.82 |
| Estimado | $-1.39 | $-1.44 | $-2.00 | $-3.25 |
| Sorpresa | — | +13.9% | -11.5% | -17.5% |
| Métrica | KPTI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -62.1% | -38.6% | -23.5% |
| Net Margin | -134.2% | -33.6% | -100.7% |
| FCF Margin | -51.6% | -13.9% | -37.7% |
| ROE | — | -40.4% | — |
| ROA | -180.8% | -32.0% | -148.8% |
| Current Ratio | 1.12 | 2.84 | -1.72 |
| Debt / Equity | — | 0.28 | — |